Inspire Medical Systems, Inc. (INSP)

Inspire Medical Systems, Inc.'s stock has experienced volatility over the past six months. The stock price saw a significant plunge in January 2026, and reached a 52-week low of $64.77 on February 6, 2026, influenced by coding headwinds and a clarification from CMS. Investor sentiment improved in November 2025, with the stock rising significantly on separate occasions. The company reported strong third-quarter 2025 earnings, and announced a $200 million stock buyback plan in August 2025. A class-action lawsuit was filed against the company in November 2025.

Analysis of Inspire Medical Systems, Inc.'s seasonal charts over the past seven years suggests a period of seasonal strength. A "Buy Date" of November 24 and a "Sell Date" of February 26 has historically resulted in a geometric average return of 15.08% above the S&P 500 Total Return Index. This timeframe has shown positive results compared to the benchmark in seven of those periods. However, it is important to note that only seven years of data are available, which may be insufficient to create a fully reliable seasonal profile. The company's seasonal timeframe correlates poorly with the broader Healthcare sector's seasonal strength, which typically runs from April 25 to December 4.

Inspire Medical Systems, Inc. specializes in neurostimulation technology to treat moderate to severe obstructive sleep apnea. Its primary product is the Inspire system, which includes implantable components and a remote control. This system works by continuously monitoring a patient's breathing and delivering mild hypoglossal nerve stimulation to maintain an open airway during sleep. The company has developed and launched newer versions, such as the Inspire V neurostimulation system, which aims to improve performance and simplify surgical procedures.

Inspire Medical Systems, Inc. has a geographic footprint that includes the United States and international markets. The majority of its revenue is generated from the United States. Internationally, the company sells its Inspire system in select countries in Europe and Japan through a direct sales organization, and in Singapore and Hong Kong through distributors.

Inspire Medical Systems, Inc.'s brand reputation has been impacted by a class-action lawsuit filed in November 2025, alleging misleading statements regarding the launch of its Inspire V system. Despite this, the company has also presented positive safety and efficacy data for its Inspire V system at industry meetings, highlighting enhanced performance and successful device implants.

Inspire Medical Systems, Inc. has a significant institutional ownership base, with 687 institutional owners and shareholders holding a total of 39,526,673 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Citadel Advisors Llc, William Blair Investment Management, Llc, Deerfield Management Company, L.p. (series C), and State Street Corp. Institutional ownership accounts for approximately 87.16% of the company, while individuals hold about 0.87%.